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Insulin is used in infusion solutions for various 
purposes. Some indications for such use are for treatment 
of diabetic coma, post myocardial infarction and prevention 
of catabolic response to severe trauma associated with 
burns. 
Non-specific surface adsorption of insulin to infusion 
bottles and their administration sets has been reported by 
various workers. However, the extent of adsorption is not 
clearly defined by these studies .. 
Lack of quantitative adsorption data makes it dif-
ficult for a physician to determine the actual amount of 
insulin received by a patient against the amount added to 
the intravenous infusion system. This project was therefore 
initiated to determine quantitatively the extent of adsorp-
tion that would occur in a clinical setting. 
In order to achieve the above aim, varying amounts 
of carrier insulin containing 131I-labeled insulin were added 
to the intravenous infusion delivery system. Using the most 
commonly utilized mode of delivery and flow ra.te the tagged 
insulin solution was allowed to flow through the intravenous 
delivery system. Both the amount of activity delivered and 
1 
2 
the amount of activity remaining in the system were measured. 
A graphic presentation of the data was developed. 
This graph would act as a nomograph whereby the clinician 
may extrapolate the amount of insulin to be added to the 
infusion bottle in order for his patient to receive a pre-
determined dosage. Thus, fhis graph will.give the physician 
a tool, which will aid in the prescribing for various insulin 
------·derrci.-errt-rrat-Iro-fugi c s La t es. 
REVIEW OF THE LITERATURE 
Large volume parenterals intended to be adminis-
tered intravenously are frequently called ''intravenous" 
(IV) fluids or infusion fluids. They are single dose units 
packaged in suitable glass or plastic containers. They are 
sterile, pyrogen free and free of particulate matter. The 
most common use of intravenous fluids include the correc-
tion of electrolyte disturbance, fluid imbalance in the body 
and a means of providing basic nutrition (1). Some other 
uses are parenteral hyperalimentation and as a vehicle for 
the delivery of drugs. 
Continuous slow infusion delivery of a drug has 
three advantages. The first, and most important, is in a 
crisis situation since this mode of delivery is very rapid. 
Secondly, a very specific- and continuous blood level of the 
active medicament can be achieved by. closely controlling the 
influsions flow rate. The third reason is that this mode of 
delivery is preferred by hospital staff as well as the patient, 
because by influsion deli. very one can avoid repeated doses, 
consequently less discomfort to the patient. 
This delivery system is ideal, providing no incom-
patibilities exist and the integrity of the solution remains 
stable. However, not all drug additives to infusion systems 
3 
4 
enjoy this freedom from incompatibility. Large volume fluids 
have their own therapeutic uses. They were not formulated 
to act as a vehicle for other drugs. Likewise, parenteral 
drugs used as IV additives are not necessarily formulated 
to remain stable and active when added to one of a variety 
of large volume fluids (2). However, current medical prac-
tice often requires the addition of drugs to these solutions 
_____ A rtd-t-b.-u.s4b.-e-po-t-e-n-t-:l-a-1-Il1!-0-B-l-em-e-f-}3-a--P-en-t-e-r---a-l-i-n-e-em~-a-t-i-6-i-1-i-t-i-e·so----
arises. 
Incompatibilities can be divided into three categories: 
therapeutic, physical and chemical. Therapeutic incompati-
bilities occur when two or more drugs administered concur-
rently result in an undesirable antagonistic or synergistic 
pharmacologic action (3). When the combination of two or 
more drugs in solution results in a change in the appearance 
of the solution, such as color, formation of turbidity or 
precipitate, or the .evolution of gas, it is called a physical 
incompatibility (4). Finally, degradation of drugs in 
solution resulting from the combination of parenteral dosage 
forms is called chemical incompatibility (5). The majority 
of these incompatibilities resulting from hydrolysis, oxida-
tion, reduction or complexation can be detected only through 
analytical methods. 
Insulin administered by continuous infusion has been 
documented to have a definite affinity for glass, polyvinyl-
chloride and many other inert surfaces. Therefore, insulin 
may be considered both physically and chemically incompatible 
5 
with the surface of its container. 
In 1951, Ferebere, Johnson, Mithoeffer and Gerdella 
( 6), working on the radioiodination of insulin, observed 
that insulin in dilute solution, at pH 7, was adsorbed to 
a significant degree to laboratory glassware. rhis adsorp-
tion was demonstrated by a rapid disappearance of radio-
activity at pH 7 with a rapid return on the addition of strong 
alkali. They also noted that the addition of bovine albumin 
in a final concentration of 0.5% prevented or delayed this 
adsorption (7). Reeves and Franks (8), working with 1311-
albumin in 1956, also noticed a loss of radioactivity under 
similar circumstances. 
Hill, in 1959 (9), found that radioactivity had been 
lost from aqueous iodinated insulin solutions which were 
stored in pyrex or siliconized glassware and in polyethylene 
reagent bottles. This adsorption occurred when a solution 
of 131I-insulin was diluted without accompanying albumin. 
A rapid loss of radioactivity from solution took place before. 
the solution could be mixed and an aliquot sampled. These 
observations are in agreement with a previous report by 
Bull, 1956 (10), concerning the adsorption of bovine serum 
albumin to glass. Hill (11), using graduated cylinders sur-
rounded with x-ray film, further demonstrated the ability 
of 5% gelatin to confine the radioactivity within the limits 
of the solution. He showed that upon emptying these cylinders 
containing 5% gelatin only negligible radioactivity was 
retained by glass (11). 
6 
In 1959 F:ceinkel and Goodner (12), in their prelim-
inary study related to insulin metabolism by human placental 
tissue, demonstrated variation of insulin adsorption with 
variable insulin concentration. They observed that after 
incubation at.38°C for 30 minutes the percent adsorption of 
insulin to glass decreased as the concentration of insulin 
in solution increased. In addition, they also observed the 
s i g n i f i can c e of huma_n_serJJ.ID-~ l_b-u..rn-i-n-\-!!S-..A...---':)-i-P..---t-he-!71"'-e-v-e-n-t-i-oor-------
of insulin's adsorption. By using varying concentration of 
HSA and a 0.25 ].lgjml concentration of insulin, they showed 
that without HSA at least a 47% loss of radioactivity in the 
beaker would occur (13). 
Wiseman and Baltz, in 1961 (14), substantiated the 
findings by demonstrating that when no carrier protein was 
present, a 20.9% loss of insulin-131 by adsorption resulted 
within 30 minutes. However, when 0.1 mgjml of HSA was added 
to the incubated sample, a nearly three-fold decrease in adsorp-
tion to the glass was observed and at a concentration of 
0.5 mg/ml HSA only 1.8% of the total radioactivity remained 
adsorbed to the beaker ( 15). 
Sonsken found that the addition of unlabeled insulin 
was an effective method of preventing the adsorption of labeled 
insulin to glassware (16). 
In the early 1960's, human serum albumin was used 
routinely to prevent adsorption of insulin to glass surfaces. 
HSA was used most commonly in preventing adsorption during 
the preparation of 1311 and 125I radioiodin~ted protein.. In 
7 
this process, gel-filtration was utilized to separate the 
labeled proteins from their reaction mixtures. In 1962, 
Hunter and Greenwood (17) prior to their filtration of human 
growth hormone labeled with 131r, first passed bovine serum 
albumin through the gel-filtration dextran column. 
This was done to prevent adsorption and to ensure a maximal 
elution yield of their labeled compound. 
----------=J~erjEa_and_GibsDn_,---in-l962-(-lB-}-,-r.:oJ-lE>G-ted---ge lc--------
filtration eluates of pure insulin r 131 in a barbitone 
buffer containing 0.025% human serum albumin. In 1965, 
Anghileri carried out a stability study of high activity 
131 r labeled insulin utilizing a borate buffer and commer-
cially available HSA (19). In 1965, Banerjee again working 
with the preparation of 1311-insulin used a 100 ml flask 
·containing 50 m1 of 0.025% HSA in a barbitone buffer to collect 
1 ml pure 131 r-insulin eluate: (20). He also recommended a 
similar solution containing HSA ·for. storage of 1311-insulin 
for periods up to 14 days. 
Weisenfeld, et al. , 1968 ( 21), were the first to 
report on the loss of insulin by adsorption when it is admin-
istered by intravenous infusion for therapeutic purposes 
(21). They confirmed insulin adsorption to glassware in lab-
oratory apparatus, and demonstrated similar loss in bottles 
and tubing used for intravenous infusion. Weisenfeld anct 
his associates added labeled 1311-insulin along with varying 
amounts of carrier insulin to 500 ml infusion bottles of normal 
saline. These bottles were emptied at various flow rates. 
8 
Th d . f 131r . ]" d b t t" 1 . 11 e a sorpt1on o -1nsu .1n prove su s an 1a espec1a y 
at low concentrations of the carrier insulin. They also in-
vestigated the use of human serum albumin in the prevention 
of insulin adsorption in the clinical situation. The pres-
ence of 0.35% HSA successfully prevented adsorption of in-
sulin to the bottles and adsorption loss to tubing was 
decreased. It was demonstrated that with HSA, 40 units of 
insulin would only suffer a 6.6% loss of radioactivity in 
comparison of 40 units of insulin, which without the addition 
of HSA suffered a 26.2% loss of radioactivity. Weisenfelld's 
group :was the first to propose the use of a carrier protein 
in the administration of insulin by way of infusion. They 
concluded that the magnitude of insulin that adsorbs to glass 
and polyvinylchloride tubing surfaces varies with many fac-
tors including: (1) concentration of the insulin, (2) rate 
of flow, (3) duration of time in contact with adsorbing sur-
face, and (4) presence of other negatively charged proteins 
(22). They further showed that turbulence, as in shaking 
or rapid flow, causes greater glassware adsorption than when 
fluid remains motionless in or flows slowly from the con-
tainer. It was also discovered that the opposite is true 
regarding adsorption to tubing. 
In 1974, Petty and Cunningham ( 23 ), further reported 
on the subject of insulin adsorption in the clinical situa-
tion. They elaborated a study ascertaining that greater 
adsorption occurred in polyvinylchloride (Viaflex) containers 
than glass containers. Evidence was shown indicating that 
9 
maximal adsorption of insulin occurred in all containers 
during the first 15 second period required for injecting, 
inversion and initial sampling. They also demonstrated 
under the conditions of this study of rapid infusion at 14 
ml per minute, that when 30 units of regular insulin was 
added, 52% was immediately adsorbed to the container wall 
and 55% of the .insulin .remaining in the container was ad-
sorbed to the wall of the intravenous tubing~f~o~r~a~~t~o~t~a~l, ____________ ___ 
adsorption of 79.0%, The results of their study using 
variable insulin concentrations showed that losses of in-
sulin after 5 minutes from bottles containing 10, 20 and 30 
units of insulin were 36%, 61% and 52%, respectively. Petty 
and Cunningham, also studied the use of HSA in the preven-
tion of insulin adsorption. Their study showed that addi-
tion of l"ml of commercial HSA solution (25%) decreased the 
loss with 30 units of insulin from 52% to 28% (24). Although, 
Petty and Cunningham demonstrated poorer efficiency of HSA 
in preventing insulin adsorption than did Weisenfeld and 
associates, it must be noted that Weisenfeld's group utilized 
a 28 fold higher concentration of HSA in their solutions. 
Kraegen et al., 1975 (25), studied the different 
carrier sblutions for low level intravenous insulin infusion. 
Their experimental design involved detection of insulin by 
radioimmune assay (RIA). Results indicated significant 
losses of 60-80% of insulin in normal saline. They concluded 
that it was therefore necessary to add protein to the solu-
tion and maintain a constant delivery rate in order to minimize 
10 
losses. Recovery studies showed that 3.5% pargeline (de-
graded gelatin) solution was a suitable medium for their 
purpose, offering some advantages over HSA. Semple et al., 
1975 (26), showed data that carrier solutions are indeed 
necessary in the slow intravenous infusion of insulin. 
Sonsken, 1976 (27), after working with insulin infusions 
insisted that carrier protein always be added to low dose 
continuous infusions containing insulin. He prooosed the 
use of either human serum albumin or plasma protein to act 
as the carrier. Contrarily, Oakley, 1976 (28), stated 
that the addition of human serum albumin is not necessary 
in low dose insulin infusion. He further indicated that 
insulin at a concentration of about l unit/ml does not sig-
nificantly adhere to plastic. 
Peterson et al., 1976 (29), investigated measures 
for preventing insulin adsorption to polyvinylchloride con-
tainers and tubing. Results of their study showed that if 
the total infusion system were prewashed with 50 ml of a 
solution containing 25 units of (regular) insulin in 500 ml 
normal saline, a significant decrease in adsorption would 
occur. They demonstrated that such a wash-out technique 
would produce 75% of the expected insulin in the first 50 
ml collected from the infusion system and 100% thereafter. 
They performed a comparison between their wash-out procedure 
and that with an identical infusion containing 1.25 g percent 
of HSA. In the infusion system subjected to the saline-
insulin washout, after the first 20 ml of the infusion, the 
11 
p&rcent of insulin recovered from the system was identical 
to that observed when albumin was added. From this data, 
they concluded that if at least 25 units per 500 ml is used 
and, if 50 ml is washed through the infusion apparatus be-
fore admin:i.stration, no extra protein additives would be 
necessary. Thus, since 1951, considerable research has been 
published showing the significance of adsorption of insulin 
to infusion systems. 
In recent years the administration of insulin via 
infusion has been used for new and varied indications. 
Hinton et al. , 1971 ( 30), reported the use of high dose in---
sulin infusions to reduce the catabolic response to injury 
in burned patients. In this study 50% glucose solution con-
taining at least 40 mEq per liter potassium chloride and 
120 units of insulin was administered intravenously. This 
treatment was shown to reduce the nitrogen and potassium 
loss in severely burned patients to low values which could 
be easily replaced by a normal diet. 
Allison and associates, 1972 (31), advocated the 
use of potassium-glucose-insulin (PGI) solutions. A daily 
infusion of 500-1000 ml of 50% glucose containing 100-200 
unj_ts of soluble insulin and 100-120 mEq of potassium per 
liter proved to beauseful adjunct to the management of severe-
congestive heart failure. Majid et al., 1972 (32), also 
advocated a similar PGI solution for congestive heart failure. 
They showed that PGI infusions increase cardiac output in 
both normal subjects and in patients with severe heart 
failure. 
12 
Sonsken and staff (33), demonstrated that slow intra-
venous infusions of small amounts of insulin were found to 
be highly effective in correcting the biochemical abnormal-
ities of uncontrolled diabetes mellitus. Menyel, 1973 (34), 
further showed data in agreement with Sonsken. 
Page et al. , 1974 (35), utilized slow insulin in-
fusions in treating diabetic coma. They demonstrated a 
rapid recovery in 38 patients, who were treated by continuous 
low dose intravenous infusion of insulin at an average dose 
of 7.2 .units per hour. Kidson et al.,(36), were successful 
in using continuous intravenous infusion of insulin. Infusing 
2.4 units per hour led to rapid recoveries from severe dia-
betes mellitus. Semple et al. ,(37),went on to show additional 
indications of slow intravenous insulin infusion. They in-
fused from 4 to 6.5 units per hour leading to dramatic re-
coveries in patients with diabetic ketoacidosis. Vaisrub 
( 38), f·urther substantia ted this mode of therapy in ketoacidosis. 
Kaufman and his associates, 1975 (39), also obtained good 
results from low dose insulin in patients with diabetic 
ketoacidosis. Slama et al. , ( 40), showed the feasibility of 
slow continuous insulin infusion without blood glucose 
monitoring for several days in ambulatory patients. 
It is evident that the current practice of adding 
insulin to an infusion system intended for intravenous de-
livery is widespread. There are a number of clear advant-
ages to this mode of therapy. It provides a steady serum 
concentration of insulin in the effective range, avoiding 
13 
the peaks and valleys i.n serum levels that occur wi.th inter-
mittent dosage regimens. Since the serum half-life of in-
sulin is short, of the order of 3-4 minutes, serum levels 
can be titrated and maintained quite precisely. Thus, this 
method is not only simple in administration but also easily 
controlled. 
However, it is also very important if not mandatory, 
that the physician be aware of the precise amount oi__in_Slllin ____ _ 
his patient is receiving. Up until now, the criteria for 
determining the quantity of insulin to be incorporated into 
an infusion system has been purely an art. These judgments 
are based initially on laboratory results and then on previous 
experiences of the prescribing physician. 
Whether a carrier solution be utilized or not, is 
still highly disputed. As noted earlier, studies conducted 
by Page, Kidson, Semple and their respective associates did 
not employ a carrier protein to reduce insulin adsorption. 
Yet, they indicated the exact number of insulin units per 
hour their patients received. These reports, incredibly, 
never took into consideration the fact that the phenomenon 
of insulin adsorption had indeed occurred. 
Presently, the intended dosage of insulin as opposed 
to the number of insulin units actually received by the 
patient j_s inconsistent. In order to allow the administra-
tion of j_nsulin through such a delivery system to become 
more consistent a closer inspection into the adsorption of 
insulin must be conducted. By simulating the normal clinical 
14 
administration of insulin via infusion, the location of 
insulin's adsorption and the actual dosage received by the 
patient can be realized. This knowledge would enable 
the clinician to extrapolate the additional amount of in-
sulin necessary per infusion bottle in order to attain a 
predetermined dosage. 
It is the goal of this project, therefore, to 
in providing optimum insulin therapy. 
EXPERIMENTAL 
Determination of the Purity of 
the Labeled Compound Received 
The Iodine-131 labeled insulin was prepared at the 
The procedure used was that described by Bannerjee, 1962 
(41). It results in the yield of an initially pure Iodine-
131 tagged insulin of a very high specific activity. 
The preparation of a high specific activity Iodine-
131 insulin in a relatively pure state is essential. It is 
also essential that prior to the use of this radiolabeled 
compound in an experimental design, its purity still be 
intact. The purified state, however, cannot be maintained. 
The high activity present causes radiolytic brea~down of the 
insulin moiety resulting in the release of free Iodine-131 
in the sample. The rate of breakdown and separation of the 
radioactivity from the insulin molecule depends upon the 
amount of specific activity, the higher the activity, the 
greater the breakdown. 
Therefore, it was necessary to determine the extent of 
free Iodine-131 present before using the preparation in this 
experiment. This was accomplished by Instant Thin Layer 
15 
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ChromfJ. tography ( ITLC). 1 
On a daily basis, a 5 em x 20 em ITLC, Type SG 
(silica gel) strip, was spotted with the high activity mix-
ture and immediately dried by nitrogen gas. The dried ITLC 
strip was then placed in a chromatographic chamber using 80% 
methanol as the solvent. After the solvent had traveled 
approximately 5 inches (12 em) up the strip (20 minutes), 
-------t·;tm-rrcc sr;r:Lp was removed and allowed to air dry. The strip 
was "then cut into 1/2 inch (1. 28 em) segments starting with 
the first segment being l/4 inch (0.64 em) above and below 
the origin and the last 1/2 inch (1.28 em) segment being 
1/4 inch (0.64 em) above and below the solvent front. Each 
1/2 inch (1.28 em) segment was then placed in a counting 
tube and counted. The activity was counted by a Harshaw 
Integral LineR well-type scintillation detector. The phos-
phor was a 2" x 2" thallium activated sodium iodide crystal 
with a well 3/4 inch in diameter and 1-1/2 inches deep. 
The Nai(Tl) crystal is coupled to a photomultiplier tube. 2 
The photomultiplier tube is connected by way of 
cables to the OrtecR counting assembly. 'This assembly is 
designed to proportionately measure the activity of samples 
placed in the well detector and includes a preamplifier, 
1Instant Thin Layer Chromatography-Silica Gel impreg-
nated glass fiber sheets, Lot #270623, Gelman, Ann Arbor, 
Michigan. 
2Harshaw Nai(Tl) scintillation detector and photo-
multiplier tube, Type 7858, serial no. EC623, The Harshaw 
Chemical Co., Cleveland, Ohio. 
17 
ampli.fier, high voltage power supply, single channel analyzer, 
discriminator scaler and timer. 3 The entire detecting 
apparatus was calibrated for the gamma emission character-
istic of I-131 prior to its use. 
Significant amounts, 30-50%, of free I-131 had indeed 
separated from the insulin molecule as evidenced by very high 
counts observed at the solvent front. The presence of the 
separated free I-131 indicated the need for a means of 
purification immediately prior to its use. 
Purification of the Labeled Compound: 
Iodine-131 Insulin 
The procedure used to remove the damaged insulin and 
free iodine from the intact Iodine-131 labeled insulin was 
described by Banerjee (42). This process, which is now com-
monly used in the purification of Iodine-131 insulin, util-
izes gel-filtration. The procedure in this portion of the 
experiment employed a 10 ml pipette, as a chromatographic 
column. The pipette was equipped with a stopcock and packed 
25 em up the length of the column with Sephadex G-50 l.ledium. 4 
Initially, two 0.2 ml samples of a 25% solution of 
Human Se:rum Albumin (HSA) 5 were passed through the column 
3ortec Preamplifier 11odel 113, Ortec Amplifier Model 
485, Ortec High Voltage Power Supply Model 456, Ortec Single 
Channel Analyzer Hodel 406A, Ortec Discriminator Scaler Model 
429, Ortec Timer Model 719, Ortec Inc., Oakridge, Tenn. 
4 "' Lot " 8341-M, Pharmacia, Uppsala, Sweden. 
5cutter Laboratories, Berkeley, California. 
18 
to prevent the adsorption of insulin. This was followed by 
the passing of 0.1 ml of a large molecular weight blue dye 
(bromphenol blue) through the column. The dye was used to 
determine the bed volume and the void volume of the packed 
column. This was immediately followed by the addition and 
and passing of l. 5 ml of the heterogenous Iodine-131 labeled 
insulin mixture as supplied. To insure the most efficient 
removal of the purified iodine-1.31 labeled insulin,,__,t .. h"-'e"--------
sample was collected over the selected peak activity range 
of the eluation. This was accomplished through monitoring 
the level of activity by way of periodically collecting 
and counting the activity of one drop of eluate coming from 
the pipette. Collection was started and terminated when a 
predetermined level of activity was obtained. The sample 
volume ranged from 3-4 ml and was collected in a 10 ml 
Type I glass vial previously rinsed with 0.35% solution of 
HSA. Immediately following collection, a sample of the 
eluate was spotted on the ITLC paper and as before checked 
for purity. When performed on a daily basis, the results 
indicated a relative purity on the order of 90-95%. 
Procedure for the Determination of 
Insulin Adsorption to an Infusion 
Delivery System 
The high activity purified eluate was then suitably 
diluted. The. dilution was such that when 0.5 ml of the 
eluted labeled insulin was diluted by 1000 ml infusion solu-
tion, a 2 ml counting sample would yield approximately 10,000 
counts per minute (cpm). 
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Iodine-131 labeled insulin, 0.5 ml, together with 
carrier6 insulin in concentrations 10, 20, 40, 60, 80, an 
100 un'its were used. Each insulin concentration along with 
the radioactive tracer insulin was added simultaneously to 
three separate 1000 ml bottles of Dextrose 5% in water. 7 
Following the addition, each bottle was shaken manually. 
After one minute of shaking, the bottle was opened and a 2 
ml sample was removed using a disposable pipette8 and placed 
in a counting tube. The rubber stopper was replaced and an 
administration set9 attached. The bottle was inverted and 
the solution was calibrated to flow at a rate of 125 mlfhr .. 
(8 hr bot'tle) into a 1000 ml collecting beaker. 
The collecting vessel was especially prepared to pre-
vent insulin adsorption. Each plastic 1000 ml beaker was 
filled with a 0.35% solution of HSA and covered with saran 
wrap to reduce evaporation. The beakers were then placed 
under refrigeration for 24 hours prior to use. Before .col-
lecting the insulin solution in the beaker, the HSA solution 
was poured out and the saran wrap covering replaced. A 
piece of paper tape was then placed on the saran wrap over 
the center of the beaker's opening. This was followed by the 
6u-lOO Regular Insulin, Lot No. 4Ll4153, E.R.Squibb and 
Sons, Princeton, New Jersey. 
7Lot No. 60-885-DM-02, Abbott Laboratories, North 
Chicago, Ill. 
8Micropipettes accurate to the nearest 0.001 ml cali-
bration, Schwartz/Mann, Orangeburg, N. Y. 
9surgical Venoset No. 1703 (178 em), Abbott Laboratories, 
North Chicago, Ill. 
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attachment of a 21 gauge, 1-1/2 inch needle to the admin-
istration set and insert.ing the needle midwa-y through the 
paper tape. Just prior to starting the flow of solution 
100 units of unlabeled insulin were added to the beaker to 
further prevent insulin's adsorption to the collecting 
beaker. 
During the flow of the solution containing the car-
rier insulin and iodine-131 labeled insulin, samples were 
withdrawn at specific intervals. These 2 ml samples were 
removed from the collecting beaker using disposable micro-
pipettes after 1, 4, and 8 hours. Each aliquot was then 
placed into a counting tube, capped and set aside for later 
counting. 
In order to determine the initial loss of insulin 
adsorbed to the infusion bottle after one minute and also 
at the subsequent intervals of 1, 4, and 8 hours, a standard 
was developed. This standard or control represented the 
concentration of insulin in the infusion bottle when no 
adsorption had occurred. This was done by preparing an 
identical dilution of tracer insulin in a counting tube as 
that which exists in the 1000 ml infusion bottle. 
A 10 ml volumetric flask was first rinsed.several 
times with 0.35% solution of HSA and then finally 5 ml of 
the HSA solution was left in the flask. This was followed 
by the addition of 0.1 ml, 10 units, of U-100 unlabeled 
insulin to the volumetric flask. This mixture of HSA and 
insulin was prepared to prevent adsorption of the I-131 
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labeled insulin (tracer) to the volumetric flask. One 
tenth milliliter of the suitably diluted purified eluate 
of tracer insulin was then added to the volumetric flask 
containing the HSA and insulin mixture. The volume was 
then adjusted to 10 ml with distilled water. After mixing, 
three 0.1 ml samples were removed from the volumetric flask 
at various depths and added to separate counting tubes. To 
each tube was added L 9 ml of distilled water rendering a 
total volume in each tube of 2 ml (the same volume of each 
counting tube). The dilution, on a volume basis, of the 
tracer insulin was identical (1:1000 or 0.001 ml of tracer 
insulin per 2 ml sample) in both the experimental and the 
standard control tubes. Therefore, if no adsorption occur-
red, the concentration of the tracer insulin in both the 
experimental tubes and the devised standard control (ref-
erence) tube would be identical, i.e., their counts per 
minute would be nearly the same. 
The three control· samples of each insulin concen-
tration run were averaged together to yield the absolute 100% 
value. This value represented the state when no insulin 
adsorption takes place and was used as a reference whereby 
the qxtent of insulin adsorption could be calculated for 
each of the three bottles over the 8 hour period. Therefore, 
each subsequent sample counted would represent that fraction 
of the initial dose still remaining in solution. 
DE,termination of the Nature of Insulin 
Adsorption to the Administration Set 
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After each set of three infusion bottles completed 
their 8 hour flow, the administration set from each bottle 
was removed and examined for the location and degree of in-
sulin adsorption. 
This was accomplished by first cutting the_drip 
chamber of the administration set into four equal. sections 
and folding one of these segments in half and placing it 
at the bottom of a counting tube. Also, three l-3/4 inch 
segments of the administration set tubing were removed: 
l) at the top just below the drip chamber, 2) at the center, 
and 3) just above the area of needle attachment. All seg-
ments were measured and cut identically on each administra-
tion set so a comparison could be made. 
Each l-3/4 inch segment. was folded in half and placed 
at the bottom of a counting tube. A l-3/4 inch length seg-
ment was chosen because.when folded in half it most closely 
simulated the same geomet-ry of the counting tubes when con-
tai.ning their 2 ml aliquots. 
All counting tubes representing a particular concen-
tration of carrier insulin were counted at the same period 
of time. The length of time elapsed between counting the 
first and last tube was less than two hours. Therefore, 
the need to calculate back to zero time was negligible. 
'rABLE I 
ACTIVITY IN INTRAVENOUS SOLUTIONS AND 
ADMINISTRATION SETS 
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Activity in counts per minute 
Trials 1 2 3 
10 Units of Tagged Insulin 
Control (100%) 11,459 11 '803 10,988 
----------~ll--~Q~~l€--~--~--------------------------~--~------------~----------
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TABLE I. Continued 
Activity in counts per minute 
Trials 1 2 3 
In Beaker 
1 hour 8,569 7,930 7,360 
4 hours 8,510 7,715 7,612 
8 hours 8,914 7,493 7,559 
Administration Set 
Drip Chamber Section 12,475 7' 116 6,307 
Top Tubing Segment 18,956 19,723 16,219 
Middle Tubing Segment 6,916 6,958 5,968 
Bottom Tubing Segment 8,237 11,749 9,753 
60. Units of Tagged Insulin 
Control (100%) 15,032 14,632 14,998 
In Bottle 
1 minute shake 13,470 14,639 13,883 
In Bef!.ker , hour 9,969 10,670 9,368 ~ 
4 hours 9,975 10,270 10' 149 
8 hours 9,708 9,860 9,780 
Administration Set 
Drip Chamber Section 11' 030 17,386 12,481 
Top Tubing Segment 21,943 17,668 15,809 
Middle Tubing Segment 6,150 6,560 5,645 
Bottom Tubing Segment 8,414 9,914 9,559 
80 Units of Tagged Insulin 
Control (100%) 10,328 10,607 10,460 
In Bottle 
1 minute shake 10,560 10,144 10,256 
In Beaker 
l hour 7,042 7,023 7,093 
4 hours 9, 011 8,422 8,900 
8 hours 8,318 8,214 8,150 
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TABLE I. Continued. 
Activity in counts per minute 
Trials 1 2 3 
Administration Set 
Drip Chamber Section 7,328 7,970 9,053 
Top Tubing Segment 12,771 15,364 15,125 
Middle Tubing Segment 5,394 6,187 6,429 
Bottom Tubing Segment 7,156 8,372 8,107 
100 Units of Tagged Insulin 
Control (100%) 8,996 9,083 8,889 
In Bottle 
l minute shake 8,274 8,823 8,761 
In Beaker 
1 hour 7,521 7,597 7,705 
4 hours 7,342 7,388 7,249 
8 hours 7,114 7,202 7,088 
Administration Set 
Drip Chamber Section 3,791 3,871 3,130 
Top Tubing Segment 8,944 9,671 9,642 
Middle Tubing Segment 3,836 4,148 4,994 
Bottom Tubing Segment 7,074 7,366 5,688 
TABLE Il 
CALCULATED UNITS OF INSULIN REMAINING 
IN SOLUTION (UNADSORBED) 
Insulin Units Bottles 
Still in Solu-
tion after: 
1 2 .3. 
10 Units Insulin 
On_e__mirurt_e_mam __ 1 
shaking 9.6 9.7 9.49 
One hour 6.28 6.23 6.96 
Four hours 6.2 6.26 6.7 
Eight hours 5.99 6.10 6.27 
20 Units Insulin 
One minute manual 
shaking 18.73 17.39 17.96 
One hour 13.53 13.85 14.5 
Four hours 13.41 13.32 14.34 
Eight hours 13.12 13.18 13.74 
40 Units Insulin 
One minute manual· 
shaking 36.14 34.89 37.37 
One hour 29.88 27.65 25.67 
Four hours 29.68 26.90 26,55 









Table II. (continued) 
Insulin Units Bottles Control 
Still in Solu- Average 
tion after: 1. 2. .3 (.cpm) 
60 Units Insulin 14,887 
One minute manual 
shaking 54.29 59.0 . 55.95 
One hour 4<J.T7 43.0 37.76 
Four hours 40.2 41.39 40.90 
Eight hours 39.13 39.74 39.42 
80 Uni.ts Insulin 10,465 
One minute manual 
shaking 80 77.55 78,4 
One hour 53.83 53,69 54.22 
Four hours 68.88 64.38 68.04 
Eight hours 63.59 62.79 62.30 
100 Units Insulin 8,989 
One minute manual 
shaking 92.05 98.15 97.46 
One hour 83.67 84.51 85.72 
Four hours 81.68 82.19 80.64 
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Figure 1. Insulin Units Remaining in Solution after a IOU 
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:Figure 2. Insulin Uni.ts Remaining in Solution a;fter a 
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Figure 3. Insulin Units Remaining in Soluti_on a;f;ter a 
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~igure 4. Inscili.n Units Remaining in Solution a;f:ter a 


























































Figure 5, Insulin Units Remaining in Solution after an 
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F:j.gure 6. Insul;i:n Units Remaining in Solution a:eter a 





AVERAGE INSULIN UNITS ADSORBED AND 
REMAINING IN SOLUTION 
Elapsed Time 
Units of Insulin 1 min 1 hr 
10 Units Insulin 
4 hr 
UnHs Remaining in Soln. 9.62 6.49 6.39 
_____ __:,%--Remaining_in_SolrL ___ ___,lfL2_0 __ 6_4_._9_0 __ 6_3_._9J) 
Adsorbed Units 0.38 3.51 3.61 
%Adsorbed 3.80 35.10 36.10 
20 Units Insulin 
Units Remaining in Soln. 
% Remaining in Soln. 
Adsorbed Units 
% Adsorbed 
40 Units Insulin 
Units Remaining in Soln. 
% Remain in Soln. 
Adsorbed Units 
% Adsorbed 
60 Units Insulin 
Units Remaining in Soln. 
% Remaining in Soln. 
Adsorbed Units 
% Adsorbed 
80 Units Insulin 
Units Remaining in Soln. 
% Remaining in Soln. 
Adsorbed Units 
% Adsorbed 
100 Units Insulin 
Units Remaining in Soln. 


























































































AVERAGE INSULIN UNITS REMAINING 
IN SOLUTION VS. TIME 
Units of Insulin 
Time 10 20 40 60 
1 min 9.6 18.0 36.1 56.4 
1 hr 6.5 14.0 27.7 40.3 
4 hr 6.4 13.7 27.7 40.8 
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PERCENTAGE OF INSULIN REMAINING IN SOLUTION" 
Uoi '" of InouliO Added~ 
10 20 40 60 80 100 
.. ~- ---
96.2 90.2 90.3 94.0 98.t 95.9 
64.9 69.8 69.3 67.2 67. < 84.6 
63.9 68.5 69.3 68.1 83J 81.5 
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AVERAGE ACTIVITY OF ADMINISTRATION SET (cp~) 
Concentration of Insulin [Added 
I 
Portion of Adminis-





of drip chamber 8,889 8,573 8,633 13,362 8,117 
Top segment 18,290 18,261 18,299 18,473 14,420 
Middle segment 6,886 6,884 6,614 6,118 6,003 





























Figure 9. Average Activity vs. Each Segment F\emoved :from 












1/4 section of 
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TABr;g VI I 
·PERCENT INSULIN COLLECTED AND ADSORBED 
AFTER 8 HR VS ADDED INSULIN 
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Figure 10. Percent Insulin Collected (A) 






INSULIN UNITS DELIVERED AFTER A lOU ADDITION VS. TIME 
% of Insulin Units of InsulU~ Actual Units 
Volume Remaining in Present if Nol of Insulin 
(mls) Solution Adsorption Present 
125 64.9 1.25 0.81 
500 .63.9 5.0 3.2 














































Figure 11. Insulin Units Delivered a:f;ter a lOU 










INSULIN UNI1'S DELIVERED AFTER A 20U ADDITION ~S. TIME 
% of Insulin Units of Insulin Actual Units 
Volume Remaining in Present if No of Insulin 
(mls) Solution Adsorption Present 
125 69.8 2.5 I l. 75 
500 68.5 10.0 6.85 






































Figure 12. Insulin Units Delivered after a 20U 






INSULIN UNITS DELIVERED AFTER A 40U ADDITION Is. 
% of Insulin Units of InsuliJ 
Volume Remaining in Present if No 
Time (mls) Solution Adsorp.tion 
1 hr 125 69.3 5.0 
4 hr 500 69.3 20.0 












































F:j.gur.e 13. Insulin Units Delivered a:f:ter a 40U 










INSULIN UNITS DEL!VERED AFTER A 60U ADDITION VB. TIME 
% of Insulin 
••••• nf ·······r Actual Units Volume Remaining in Prese t if No of Insulin 
(mls) solution Adsorption .. Present 
125 67.2 7.5 5.0 
500 68.1 30.0 20.4 





































:Figure 14. lnsulin Units Delivered a;(ter a 60U 




INSULIN UNITS DELIVERED AFTER AN SOU ADDITIONIVS TIME 
% of Insulin Units of Insulin Actual Units 
Volume Remaining in Present if No of Insulin 
Time (mls) Solution Adsorption Present 
l hr 125 67.4 10.0 6.7 
4 hr 500 83.9 40.0 33.6 
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Figure 15. Insulin Units Delivered after an SOU 






INSULIN UNITS DELIVEHED AFTER A 1oou ADDITION Is. 
% of Insulin Units of Insulin 
Volume Remaining in Present if No 
(mls) Solution Adsorption 
125 84.6 12.5 
500 81.5 50.0 
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Figure 16. Insulin Units Delivered after a lOOU 










TOTAL INSULIN UNITS COLI,ECTED AFTER 8 HOURS 
AT VARYING CONCENTRATIONS 
Bottle 
1 2 3 Average I 
5.99 6.10 6.27 6.12 
13.12 13.18 13.74 13.35 
31.09 26.13 26.36 26.25 
39.13 39.74 39.42 39.43 
63.59 62.79 62.30 62.89 
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Figure 17, Total Insulin Units Collected in 8 Hours vs. 
Added Uni.ta. 
RESULTS AND DISCUSSION 
These experiments were designed to determine the 
extent of insulin adsorption to an intravenous infusion 
delivery system commonly used in a clinical situation. In 
order to achieve this aim, conditions were simulated to 
resemble as closely as possible those which are actually 
used in practice. The following criteria were especially 
given attention: infusion solution, insulin concentration 
and flow rate of solution through the system. The 1000 ml 
infusion bottles were allowed to flow for 8 hours since 
this is often the optimal flow rate used in therapy. The 
vehicle most commonly used and'also reported in the litera-
ture is Dextrose 5% in water and the insulin concentrations 
used in the study cover the various ranges used in insulin 
therapy. 
The use of Iodine-131 labeled insulin proved success-
ful in determining the extent of insulin's adsorption. Table 
I (pp. 23-25), indicates that the activity (cpm) of each set 
of 2 ml aliquots removed at 1 minute, 1, 4, and 8 hours for 
a particular concentration remained very similar. Table II 
(pp. 26-27) indicates the number of actual insulin units 
still remaining in solution for each bottle. When the data 
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in Table I I ·was plotted, Figures l-6 (pp .. 28-33 ) , it further 
demonstrated the efficiency of radiolabeled techniques and 
the reproducibility of data. 
The information obtained in these experiments demon-
strated that the adsorption of insulin to the infusion delivery 
system is indeed significant. The majority of insulin diluted 
in an infusion mixture is lost within the first hour (Figures 
-------"l-6-'r.--Tlru data obtained indicate that the amount of insulin 
adsorbed to the infusion system over the eight hour period 
of flow is predictable. In the first hour of flow only 64.9% 
of a 10 unit insulin addition will be remaining in solution. 
In eight hours, after the bottle has completely emptied into 
the collecting beaker, 61.2% of the original 10 units remains 
in solution. Therefore, when 10 units of insulin is added 
to a 1000 ml infusion mixture Qf Dextrose 5% in water, it 
will undergo an initial 35.1% (3.5 units) loss during the 
first hour of flow. This is followed by only an additional 
3.7% loss of insulin occ~rring gradually during the remaining 
7 hour life of the contents of the infusion bottle (Table III, 
p. 34; Figures 7 and 8, pp. 36,38). Except for the first 
four hours of the 80 unit concentration, this interpretation 
of data can be performed for all doses of insulin. The prob-
lem in the 80 unit dosage was that for the first 1-1/2 hours, 
the three infusion bottles were calibrated to flow at a 
slower rate of 40 mlsfhr instead of the normal 125 mlsfhr. 
This factor, as can be seen in Figures 1-8 certainly altered 
the adsorption scheme until the next sample was taken at 
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4 hours. This occurrence provides evidence· that a slower 
rate of flow will cause an increase in insulin's adsorption. 
Similarly, Weisenfeld et al., ( 43 ), noted that increased agi ta.-
tion would increase insulin's adsorption to the infusion 
bottle, but that the oppsoite was true regarding the adsorp-
tion to the a~~inistration set. With this in mind, Table IV and 
V; Figures 7 and 8 demonstrate the extent of insulin's 
loss to the infusion bottle after one minute of shaking in 
comparison to insulin loss after 1 hour of continuous flow 
through the administration set. After one minute of shak-
ing, adsorption of insulin to the bottle appeared slight. 
However, upon attachment of the administration set followed 
by 1 hour of continuous flow a dramatic loss in insulin con-
centration occurred. This major loss can only be attributed 
to the administration set. 
The course and location of insulin adsorption to the 
administration set was distinctive. The drip chamber dis-
played uniform distribution of adsorbed insulin. However, 
this was not the case in the equidistant segments removed 
from the administration set tubing. In all 18 administra-
tion sets, the identical trend was noted. The top 1-3/4 
inch segment of the administration set tubing displayed very 
high counts. The bottom segment showed moderately high counts 
but the middle segment showed very low counts, Tables I and VI 
(pp. 23,35); Figure 9 (p. 40). Possible explanation of this 
might be that since the top segment is naturally ahead of 
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the other two segments, it has access to a highe;r.concen-
tration of insulin. The low activity of the middle seg-
ment results from a lower concentration of insulin passing 
through that portion of the tubing. The comparatively 
higher activity of the bottom segment probably is due to 
a slower flow with some stasis at the lower end of th.e. 
tubing. This decreased flow is caused by the reduced diam-
set. 
.At the end of the eight hours, a pattern can be seen 
indicating the effect concentration has on insulin's adsorp-
tion. In Table VII (p. 42); :Figure 10 (p. 43), it can be 
seen that as the concentration of insulin increases the per-
centage of insulin adsorbed decreases, Therefore, the loss 
of insulin from 10 to 100 unit dosages ranges from 38.8% 
to 20.7%, respectively. 
Several graphs could now be drawn indicating the 
number of uni.ts of i.nsulin a pati.ent would actually receive 
after a parti.cular dosage (IOU, 20U, 40U, 60U, SOU, lOOU) 
was admini.stered. Tables VIII-XIII (pp. 44, 46, 48, 50, 
52, 54), Figures 11-16 (pp. 46, 47, 49, 51, 53, 55) show 
the actual course of insulin adsorption over the eight hour 
peri.od for each dose admi.ni.stered. 
Th.e fi.nal compi.lati.on of s.ll data led to the con-
structi.on of a useful nomograph, This plot of Table XIV (p. 
56) represents the actual number of insulin units a patient 
wi.ll receive followi.ng a dosage of 1 unit to 100 units of 
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insulin. Through the use of this nomograph, Figure 17 (p. 
57), a physician prescribing a particular dosage of insulin 
will know how many units his patient is actually receiving. 
More important, however, the ideal use of this graph would 
be in extrapolating the amount of insulin necessary per 
liter infusion mixture to ensure the delivery of a pre-
scribed dosage of insulin to the patient. 
-------------1I-u-v-1.ew or these fl.ndings, there 1.s an indication 
of some type of receptor site phenomenon occurring. It 
appears as though each glass infusion bottle and polyvinyl-
chloride administration set possess a certain number of 
positively charged sites. These pseudo-receptor sites 
attract the negatively charged insulin moiety. Once attached 
the insulin molecule remains adsorbed to the inner surfaces 
and is thus, removed from the solution. 
Once these sites are coated, adsorption no longer 
takes place. This would explain the concentration depen-
dency noted throughout the data. 
The presence of such sites would also explain how 
human serum albumin and other negatively charged proteins 
successfully prevent insulin adsorption. When added prior 
to insulin, HSA attaches to these same sites located on 
the inner surfaces of the infusion delivery system blocking 
the attachment of insulin. 
Although an infusion solution may empty every six 
to eight hours, many hospitals utilize the same administration 
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set per twenty-four h.ciur period, This procedure c~.~-n be 
beneficial both economically and therapeutically in the 
infusion of insulin intravenously as long as certain ;fac-
tors are considered. When a second infusion solution con-
taining insulin flows through an administration set pre-
viously saturated with. insulin the only source of insulin 
adsorption will be within the new bottle. Under such ci;J;"-
cumstances 96.2 percent of a ·10 unit dosage and_9_5~_B_pe..._ . ..--~----­
cent of a 100 unit dosage will be delivered to the patient. 
There:J;ore, a second bottle utili.zed in such a manner will 
not require as much insulin and in addition the delivery 
of insuli.n wi.ll be more uniform. 
SUMMARY 
1. The literature concerning both the adsorption 
of insulin and the current indications and uses for con-
tinuous infusion of insulin has been reviewed. 
2. Determination of the purity followed by the 
purification of the tracer Iodine-131 tagged insulin was 
conducted on a daily basis. 
3. The tracer insulin along with specific quanti-
ties of carrier insulin (10, 20, 40, 60, 80 and 100 units) 
were incorporated simultaneously into a setting simulating 
clinically the infusion of therapeutic doses of insulin. 
In this procedure, the course of insulin adsorption to the 
infusion delivery system was determined during the average 
infusion rate. 
4. The extent of insulin adsorption initially and 
at specific intervals of time to both the infusion bottle 
and administration set was determined. 
5. The actual dosage in units of insulin delivered 
was determined at each time interval, as well as at the end 
of 8 hours. 
6. The total dosage of insulin delivered after in-
fusion completion was determined for each concentration used. 
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The result was a. graph, in which, one can extrapolate the 
dosage of insulin necessary per liter bottle to .ensure the 




The adsorption of insulin to inert surfaces has 
been known for quite some time, but the administration of 
insulin by infusion delivery is still a common mode of 
----------y"rrera •• 
The result of this project demonstrated that thj.s 
characterfstic adsorption phenomenon possessed by insulin 
does occur in the clinical situation and the amount of 
insulin actually delivered to the patient could be calcu-
lated. 
These findings would then enable the development of 
a scheme which would aid the physician when prescribing such 
a delivery system and ultimately benefit the patient. 
The data observed in this thesis demonstrated that 
the adsorption of insulin- to the infusion delivery system 
significantly alters the dosage regimen of the recipient 
patient. 
This adsorption phenomenon occurs in both the infusion 
bottle and the administration set, the major loss being within 
the administration set. The distribution of insulin adsorbed 
to the administration set tubing is variable depending upon 
flow rate through the tubing. 
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Nearly all adsorption takes place during the first 
hour after initiating infusion flow rate. This is followed 
by very little change in insulin concentration throughout 
the remaining duration of the bottle's flow. 
As the concentration of insulin increases the per-
centage adsorption decreases. 
Apparently greater initial adsorption occurs when 
system is insulin coated nearly all adsorption ceases, thus 
the additon of other negatively charged proteins will inhibit 
insulin's adsorption. 
The data from this project provided a convenient 
graph from which the physician could prescribe a desired 
dosage of insulin when administered by continuous intravenous 
infusion. 
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